GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

NCT04731272

Status	RECRUITING
Phase	Phase 2
Sponsor	University of Pennsylvania
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (8)

- \. Male or female, aged e18 years on date of consent
- \. Confirmed diagnosis of CF, defined by positive sweat test or Cystic Fibrosis transmembrane conductance regulator (CFTR) mutation analysis according to Cystic Fibrosis Foundation (CFF) diagnostic criteria.
- \. Pancreatic insufficiency defined by clinical requirement for pancreatic enzyme replacement.
- \. Abnormal glucose tolerance defined by OGTT criteria for EGI, IGT, or CFRD, or diagnosed CFRD.
- There will be no restriction on enrollment of individuals with CFRD but without fasting hyperglycemia (fasting hyperglycemia is defined as fasting glucose e126 mg/dL)

... and 3 more (see full listing online)

Exclusion (15)

- \. BMI \<19 kg/m2
- \. Presence of first-degree atrioventricular block or other evidence for cardiac conduction system or structural heart defects
- \. Pregnancy or lactation; a negative urine pregnancy test will be required at enrollment
- \. Known allergic reactions to any GLP-1 agonist, and any history of severe hypersensitivity reactions (anaphylaxis or angioedema)
- \. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2)

... and 10 more (see full listing online)

Locations (2 total)

Children's Hospital of Colorado, Aurora, Colorado, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States